Cyltezo, made by Boehringer Ingelheim, is the second interchangeable biosimilar drug approved by the FDA, following the approval of Mylan’s Semglee in July. It is the first interchangeable monoclonal antibody approved.
An interchangeable biosimilar drug is one that can be subsistuted for its reference product — in Cyltezo’s case, Humira — without the prescriber having to change the prescription. The substitution can occur at the pharmacy, similar to how generic drugs are substituted for brand-name drugs, subject to state pharmacy laws.
Cyltezo can treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis and more. It is administered subcutaneously by a physician.
Read the FDA’s full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
